Alan Mateo Acquires 40,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo bought 40,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were acquired at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

10x Genomics Stock Up 4.9 %

TXG stock opened at $11.65 on Thursday. The stock has a 50-day simple moving average of $14.13 and a two-hundred day simple moving average of $16.92. 10x Genomics, Inc. has a twelve month low of $10.63 and a twelve month high of $48.42. The firm has a market capitalization of $1.42 billion, a PE ratio of -7.66 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, equities research analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TXG. Stifel Nicolaus decreased their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. The Goldman Sachs Group decreased their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. Citigroup lowered their price target on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Wednesday, February 19th. Finally, Barclays lowered their target price on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.57.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Creative Planning purchased a new position in 10x Genomics during the third quarter worth about $214,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after acquiring an additional 1,025 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of 10x Genomics by 2,280.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,963 shares of the company’s stock valued at $880,000 after acquiring an additional 37,326 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of 10x Genomics during the third quarter worth about $438,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of 10x Genomics by 84.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 23,952 shares of the company’s stock worth $541,000 after purchasing an additional 10,935 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.